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The fragile X premutation (PM) allele contains a CGG expansion of 55–200 repeats
in the FMR1 gene’s promoter. Male PM carriers have an elevated risk of developing
neurological and psychiatric changes, including an approximately 50% risk of the fragile
X-associated tremor/ataxia syndrome (FXTAS). The aim of this study was to assess the
relationships of regional white matter hyperintensities (wmhs) semi-quantitative scores,
clinical status, motor (UPDRS, ICARS, Tremor) scales, and cognitive impairments, with
FMR1-specific genetic changes, in a sample of 32 unselected male PM carriers aged
39–81 years. Half of these individuals were affected with FXTAS, while the non-FXTAS
group comprised subcategories of non-affected individuals and individuals affected
with non-syndromic changes. The dynamics of pathological processes at the cellular
level relevant to the clinical status of PM carriers was investigated using the enzyme
AMP-activated protein kinase (AMPK), which is a highly sensitive cellular stress-sensing
alarm protein. This enzyme, as well as genetic markers – CGG repeat number and
the levels of the FMR1 mRNA – were assessed in blood lymphoblasts. The results
showed that the repeat distribution for FXTAS individuals peaked at 85–90 CGGs;
non-FXTAS carriers were distributed within the lowest end of the PM repeat range,
and non-syndromic carriers assumed an intermediate position. The size of the CGG
expansion was significantly correlated, across all three categories, with infratentorial
and total wmhs and with all motor scores, and the FMR1 mRNA levels with all the
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wmh scores, whilst AMPK activity showed considerable elevation in the non-FXTAS
combined group, decreasing in the FXTAS group, proportionally to increasing severity of
the wmhs and tremor/ataxia. We conclude that the size of the CGG expansion relates
to the risk for FXTAS, to severity of infratentorial wmhs lesions, and to all three motor
scale scores. FMR1 mRNA shows a strong association with the extent of wmhs, which
is the most sensitive marker of the pathological process. However, the AMPK activity
findings – suggestive of a role of this enzyme in the risk of FXTAS – need to be verified
and expanded in future studies using larger samples and longitudinal assessment.
Keywords: FMR1 premutation, CGG repeats, FMR1mRNA, AMPK kinase, cellular stress, motor scores, cognitive
status, white matter hyperintensities
INTRODUCTION
The premutation allele of the Fragile X (FMR1) gene, containing
CGG trinucleotide expansions ranging from 55 to 200 repeats,
is known to be associated with a wide range of clinical
manifestations depending on sex, age, and the size of the
expansion (Loesch and Hagerman, 2011; Hagerman and
Hagerman, 2013). Although the pathological mechanisms
leading to the premutation-associated conditions are not
fully understood, increased FMR1 transcription has suggested
the role of a ‘toxic’ gain of function of the elevated and
expanded FMR1 mRNA (Tassone et al., 2000). More recently,
the presence of ‘toxic’ proteins FMRPolyG and FMRPolyA,
containing polyglycine (PolyG) and polyalanine (PolyA) tracts,
respectively, and resulting from Repeat-Associated Non-AUG
(RAN) translation, has been linked to the etiology of these
conditions (Todd et al., 2013; reviewed in Boivin et al., 2017).
Pathogenic effects have also been attributed to the cellular
processes of damage response involved in repair of the loop
formations associated with the presence of premutation-size
CGG repeat expansions (reviewed by Hagerman and Hagerman,
2013).
This study is concerned with the genetic, cellular and clinical
changes occurring in older male carriers of the premutation allele;
nearly half of these individuals develop the severe progressive
disorder, fragile X-associated tremor/ataxia syndrome (FXTAS),
usually after the age of 55 (Hagerman and Hagerman, 2016). The
clinical presentation of FXTAS comprises several major (core)
features including intention tremor and cerebellar ataxia, and
white matter hyperintensities (wmhs) in the middle cerebellar
peduncles (the ‘MCP sign’) represent a major radiological
feature. However, more recent studies have shown a significant
prevalence of wmhs in the splenium of the corpus callosum
(Apartis et al., 2012; Kalus et al., 2016), or in the basis pontis
(Loesch et al., 2011) in FXTAS patients. Parkinsonism, cognitive
(memory and executive function) deficits, peripheral neuropathy,
cerebral wmhs and generalized brain atrophy have been listed
among the minor features of FXTAS (Jacquemont et al., 2004).
Neuropathological findings underlying the brain changes in
FXTAS show widespread loss of myelin and axons in cerebellar
and cerebral white matter with proportionally lesser gray matter
loss, astrocytic pathology, and an abundance of ubiquitin-positive
intranuclear inclusions in both neurones and astrocytes which
are most frequent in the hippocampus (Greco et al., 2006).
Traditionally, the diagnostic criteria for FXTAS relied upon the
presence of one major clinical and one major radiological sign
(definite), two major clinical signs or one major radiologic and
one minor clinical sign (probable), or one major clinical and one
minor radiologic sign (possible; Hagerman and Hagerman, 2007).
Obviously, evolution from ‘possible’ to ‘definite’ diagnosis as age
increases is the most likely scenario.
However, it has been noted that the scope of premutation-
associated clinical or radiological changes may extend beyond
the syndromic form – that is, FXTAS (Loesch et al., 2005a;
Loesch and Hagerman, 2011). The non-syndromic features
may include isolated cognitive decline, mood disorders such as
depression and/or anxiety, fibromyalgia, or isolated intention
tremor; similarly, neurodegenerative changes may extend beyond
the major feature of the MCP sign, which occurs in more
than a half of FXTAS cases (Brunberg et al., 2002) to involve
wmhs in supratentorial areas (Loesch and Hagerman, 2011,
and present data). Cortical and subcortical gray matter atrophy
have been reported in FXTAS (Cohen et al., 2006; Wang et al.,
2013c), with an accelerated volume decrease with age in the
brainstem (Wang et al., 2017) and in the anterior cerebellar
vermis and hemispheres (Hashimoto et al., 2011). These changes,
however, appear to be secondary to the white matter disease,
which is a major component of brain pathology in FXTAS and
beyond, contributing to a considerable brain volume loss (Loesch
and Hagerman, 2011; Hagerman and Hagerman, 2013). Several
reports based on structural MRI studies have revealed widespread
white matter degeneration, which apparently spreads posteriorly
from the frontal region with disease progression, but these studies
have mainly been limited to male carriers affected with syndromic
FXTAS (Wang et al., 2012; reviewed by Brown and Stanfield,
2015).
In this study we investigate the relationship of the level and
pattern of involvement of white matter disease and motor and
cognitive impairments with FMR1-specific genetic changes, in
a sample of older males carrying the premutation (PM) allele,
with the inclusion of two individuals carrying alleles extending
beyond PM into the ‘gray zone’ (GZ) expansion range (45–54
CGG repeats), which have also been associated with FXTAS-like
manifestations (Loesch and Hagerman, 2011; Debrey et al., 2016),
the risk of parkinsonism in males (Loesch et al., 2009b, 2013), and
the elevation of a ‘toxic’ FMR1 mRNA (Loesch et al., 2007). Half
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of the carriers included were affected with FXTAS, while the non-
FXTAS group comprised subcategories non-affected carriers and
carriers affected with non-syndromic changes. We use a semi-
quantitative visual wmhs rating based on MRI T2/FLAIR imaging
to assess the white matter lesions both within and beyond the
cerebellar peduncles, including other infratentorial structures
and deep hemispheric and periventricular regions, as well as
three motor scales and a battery of neuropsychological tests.
Furthermore, the dynamics of pathological processes relevant
to the clinical status at the cellular level are explored using
the enzyme AMP-activated protein kinase (AMPK), assessed in
blood lymphoblasts. AMPK is a highly sensitive cellular stress-
sensing alarm protein which may be activated by various cellular
stresses (Bokko et al., 2007; Hardie et al., 2012). Our results
suggest that there may indeed be hyperactivation of AMPK in a
sample of non-FXTAS PM carriers compared with the activities of
this enzyme in normal controls and carriers affected with FXTAS.
Apart from comparative analysis, we assess the relationships of
AMPK activity levels, CGG expansion size and FMR1 mRNA
levels, with the extent of the white matter lesions and the severity
of clinical involvements.
MATERIALS AND METHODS
Sample
The study was approved by the La Trobe University Human
Ethics Committee (No. 01/85). All participants gave informed
consent for their involvement. The new sample, recruited and
tested between the years 2012–2016, consisted of 24 Caucasian
male PM carriers, and two borderline PM/GZ carriers (later
referred to collectively as ‘PM carriers’). Out of the total of
26 participants, 12 subjects had FXTAS spectrum diagnosis
based on at least two core signs (of whom one individual was
classified as FXTAS only on the basis of MCP sign associated
with dementia). Eight subjects (later referred to as ‘OTHERS’)
manifested other disorders or non-syndromic changes outside
the FXTAS spectrum, including: fibromyalgia (1), dementia
(2), isolated intention tremors (3) that were associated with
minor wmh changes but no MCP sign, and panic disorder with
depression (1), and orthostatic tremor (1). Six asymptomatic
carriers were not affected and are later referred to as ‘Non-
affected.’
In addition, we included the data from six carriers with CGG
repeats within the PM range, previously recruited and tested by us
in 2004–2008, comprising four FXTAS-affected individuals, one
carrier manifesting mild ataxia with minor white matter changes
(included in the ‘OTHERS’ subcategory), and one non-affected
carrier. Altogether we included 16 FXTAS, and 18 non-FXTAS
(nine in ‘OTHERS,’ and seven in ‘Non-affected’ groups) totaling
32 PM allele carriers, though some data were missing in a
proportion of individuals from each of the three groups. The age
range was 50–81 years for the FXTAS group, 39–69 years for the
‘affected with non-syndromic changes’ group, and 58–64 years for
the non-affected subgroup, with mean values of 63.0, 61.8, and
53.7 years, respectively. Premutation CGG repeat sizes ranged
from 56 to 160, and the two individuals with GZ mutations had
45 and 54 repeats, respectively. The FMR1 mRNA levels ranged
from 2.32 to 5.38, relative to the baseline norm of 1.00 (Tassone
et al., 2004). All the carriers were recruited from fragile X families,
who were identified through clinical admissions of children with
the fragile X syndrome to the Victorian Clinical Genetics Services
(VCGS) at the Royal Children’s Hospital in Melbourne, with
cascade-testing.
In addition, 21 healthy age-matched non-carrier controls were
included for comparison of AMPK levels.
Neuroimaging Assessments
MRI scans were performed on 1.5 Tesla Siemens or General
Electric scanners and included turbo spin-echo 2 dimensional
(i) proton-density with T2 weighting and/or (ii) fluid-attenuated
inversion recovery (FLAIR) axial images with a 5 mm slice
thickness or 3D FLAIR with 1 mm voxel size.
Visual White Matter Hyperintensities (wmhs) Rating
The extent and severity of supratentorial and infratentorial deep
white matter hyperintensities (‘DWMH’), and periventricular
white matter hyperintensities (‘PV-WMH’) were evaluated
from the proton-density/T2 and/or the FLAIR images by
an experienced neuroradiologist (NT) using a visual semi-
quantitative method. The evaluation was performed blinded to
clinical data, and it was repeated 1 week apart. The DWMH
rating was based on the method described by Wahlund et al.
(2001). Since DWMH and PV-WMH are likely to result from
different pathological processes and vary in extent and severity
between different clinical scenarios (van Straaten et al., 2008),
and review of previous studies (Brunberg et al., 2002; Rivera
et al., 2010) demonstrated increased PV-WMH in FXTAS subjects
compared with normal controls, PV-WMH were separately rated
as described by other authors (Scheltens et al., 1993; van Straaten
et al., 2008). DWMHs were defined as areas of increased T2
signal >3 mm in diameter, and were rated in five regions for
each side of the brain: frontal, parieto-occipital, deep temporal
and subcortical white matter, and infratentorial regions. The
basal ganglia (BG) region, which included the deep nuclei and
capsules, was not included in the ratings. Infratentorial included
wmhs in the MCP and adjacent deep white matter of the
cerebellar hemispheres, which is one of the major criteria for
the diagnosis of FXTAS. PV-WMHs were defined as confluent
hyperintensities adjacent to the frontal or occipital horns (caps)
or the bodies (bands) of the lateral ventricles. When PV-WMH
were >10 mm they were given a score of two, and any excess
was included in the DWMH score. Respective scores were totaled
to give: total supratentorial-DWMH (‘Total Supra-DWMH’),
total infratentorial DWMH (‘Total Infra-DWMH’), and total
periventricular WMH (‘Total PV-WMH’) scores, and the sum
of these three regional summary scores was labeled as ‘Total-
WMH.’ Chronic lacunes, which were identified as well-defined
areas >3 mm with signal characteristics similar to cerebrospinal
fluid, were rare and were not included in either the wmhs
rating or in other analyses. The detailed description of the
measures used, together with illustration of the spectrum of
changes, can be found in our earlier publication (Trost et al.,
2014).
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Neurological and Neuropsychological
Assessments
Structured medical history and standard neurological motor
rating scales with established inter-rater reliabilities (Richards
et al., 1994; Storey et al., 2004; Stacy et al., 2007) were conducted
by two neurologists (ES and DZL) with relevant experience in
these scales from previous studies. Motor rating scales consisted
of the Unified Parkinson’s Disease Rating Scale Part III-Motor
(UPDRS-III; Fahn et al., 1987), the International Cooperative
Ataxia Rating Scale (ICARS; Trouillas et al., 1997), and the
Clinical Rating Scale for Tremor (Fahn et al., 1993).
The Vocabulary and Matrix Reasoning subtests of the
Wechsler Adult Intelligence Scale (Third Edition; WAIS-III)
were used to calculate a prorated Full Scale IQ score (Wechsler,
1997). Additional WAIS-III subtests were also used: Similarities
and Matrix Reasoning subtests represent verbal and non-verbal
reasoning, respectively, and thus would also be conceptualized as
measures of executive functioning, as would WAIS-III Digit Span
(total score) which was employed as a measure of attention and
working memory (Wechsler, 1997). The Symbol Digit Modalities
Test (SDMT; total score) was used as a measure of information
processing speed (Smith, 1982). Raw scores were used in all
analyses, except for prorated IQ, as this variable is already
adjusted for age.
Molecular Assessments
CGG Repeat Size
The data on CGG repeat expansion size, already available to us
from previous diagnostic testing of fragile X families at the VCGS,
was assessed using PCRs and Southern Blot analyses, with all
assays fully validated by internal and external quality assessment
to provide a precision of ±one to two repeats (Khaniani et al.,
2008; Loesch et al., 2009a).
RNA Isolation and FMR1 mRNA Expression Levels
This assay was conducted at the MIND Institute, University of
California Davis Medical Center, Sacramento, CA, United States.
Total RNA was isolated from 3 ml of blood collected in Tempus
tubes (Applied Biosystems, Foster City, CA, United States) or
from 1× 106 cells using Trizol (Life Technologies, Carlsbad, CA,
United States). The measurement of FMR1 mRNA expression
levels was carried out by quantitative Real Time qRT-PCR on
totRNA using custom-designed Taqman gene expression assays
(Applied Biosystems) as previously described (Tassone et al.,
2004).
AMPK Activity
These assays were performed as described by us previously
(Annesley et al., 2016). Lysates were prepared from confluent
cell lines (∼25 ml) grown in T75 flasks, harvested, lysed
in lysis buffer supplemented with phosphatase inhibitors
(50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA,
1 mM EGTA, 1% Triton X-100, 50 mM NaF, 5 mM sodium
pyrophosphate) then snap-frozen in liquid nitrogen. Thawed
lysates were cleared by centrifugation at 10,000 × g for
5 min. Supernatant total protein concentrations were determined
with the PierceTM BCA Protein Assay Kit (Thermo Fisher
Scientific). To concentrate the AMPK protein, one mg of
total protein was used in an immunoprecipitation experiment
using rabbit polyclonal anti-AMPKα1 antibody α1-(339–358)
(Stapleton et al., 1996) bound to equilibrated protein A-agarose
beads. The beads were recovered and washed four times
by centrifugation before being resuspended in 60 µl wash
buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 10% glycerol,
0.1% Tween-20). This was named the AMPK slurry. AMPK
activity was assayed over 10 min at 30◦C by adding 20 µl
of the AMPK slurry to 15 µl buffer (5 mM MgCl2, 50 mM
HEPES pH 7.4, 0.1% Tween-20, and 1 mM DTT) containing
100µM SAMS synthetic peptide (NH2-HMRSAMSGLHLVKRR-
COOH). Reactions were started by adding [γ-32P]-ATP (final
concentration 200 µM) and stopped by spotting 21 µl
onto P81 ion-exchange chromatography paper (Whatman, GE
Healthcare). Liquid scintillation counting (Perkin Elmer) was
used to measure the incorporation of 32P into the SAMS
peptide. Duplicates were averaged and normalized against the
average value from all the control cell lines, in each independent
experiment.
Statistical Analysis
Comparisons of individual MRI scores between the two non-
FXTAS (‘OTHERS’ and ‘Non-affected’) and the FXTAS groups
(as in Figure 1), and of activated AMPK levels between FXTAS,
the two non-FXTAS groups combined and normal controls (as
in Table 2) were conducted using the non-parametric Mann–
Whitney test, and ANOVA, respectively. The distribution of CGG
repeats and activated AMPK levels was estimated for each of
the three groups separately (as in Figures 2, 4, respectively)
using a non-parametric kernel density estimation method. The
method of least squares was used to assess the relationship
between each cognitive and motor score, and CGG size and
FMR1 mRNA levels, and between AMPK activity and genetic
and major clinical and wmhs measures. If outliers were present,
robust regression was employed to minimize the effect of the
outstanding observation on the estimated regression coefficients.
Although the PM and control participants had been group-
matched for age, we tested for the presence of any age effect
on individual measures, and the appropriate adjustment was
introduced in the regression model if the age effect was
significant. In estimating significance level of some of the
relationships we used a one-sided test, which tests the probability
of the relationship in one direction disregarding the possibility
of a relationship in other direction, and thus provides more
power to detect an effect This was applied in testing the effect
of genetic changes (CCG expansion and mRNA levels), which
are causative of clinical pathology represented by neurological
changes and white matter lesions, so that the direction of the
relationships (if any) is entirely predictable. A two-sided test was
applied in the relationship of AMPK with the clinical or genetic
status, where we tested the possibility of the relationship in
both directions, and in wmhs comparisons between the carriers’
groups.
To adjust for multiple testing, we used the false discovery
rate control (FDR), which is a recommended alternative to
Bonferroni-type error adjustments, and is a more suitable
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FIGURE 1 | Plot of medians for the major wmhs scores in individual brain
regions in the three groups: FXTAS, OTHERS, and Non-affected male carriers
of premutation alleles. Infra-DWMH, infratentorial wmhs; Supra-DWMH, sum
of frontal, parieto-occipital and temporal wmhs; PV-WMH, periventricular
wmhs; Total-WMH, sum of wmhs in all five regions. ∗p-value (two-sided)
<0.05 for comparison between FXTAS and combined non-FXTAS, and
between FXTAS and OTHERS for total infra DWMH. #p-value (two-sided)
<0.05 for comparison between FXTAS and Non-affected for Total WMH.
approach for drawing statistical inferences in our study
(Glickman et al., 2014). Although the Bonferroni correction is
better known and used more frequently, it tests a composite null
hypothesis about the data based merely on the number of tests,
at the cost of testing the significance of individual component
hypotheses; while FDR considers a distribution of the p-values
across individual tests, as well as their number, and ensures
greater power, at the cost of some underestimation of FDR.
All analyses were performed using STATA statistical software
(version 13).
RESULTS
Sample Characterization
Since white matter degeneration has been considered the most
prominent feature of brain pathology associated with PM
alleles and often precedes clinical manifestations of FXTAS, we
first ascertained if the degree and/or location of this process
differs between the three initially distinguished clinical groups
comprising subjects diagnosed with FXTAS, those affected with
non-syndromic changes (‘OTHERS’),’ and not affected carriers
(‘Non-affected’). Data in Figure 1 show the distributions of
median wmhs scores in individual brain regions separately for
each of these three groups. The intermediate position of the
OTHERS group in relation to the other two groups with respect
to the total wmhs (WMS) score is noticeable, although differences
between small samples in the remaining regional wmhs scores
were not significant.
The intermediate position of the OTHERS group is
more evident when all three clinical categories of carriers
are distributed in relation to the CGG repeats within the
PM/upper-end GZ range. The data in Figure 2 show that
the distribution for carriers in the Non-affected group peaks
at the level of 55–60 CGGs, the distribution for individuals
with FXTAS ranges between 65 and 120 CGGs (peaking at
∼85 repeats), and the carriers in the OTHERS group assume
an intermediate position with some overlap with each of
the other two groups. Although the intermediate position
of the group representing non-syndromic pathologies is an
important finding, the sizes of both non-FXTAS groups are
too small to be considered separately. They were therefore
combined into a ‘Non-FXTAS’ group for statistical analysis.
Distributions of individuals in FXTAS and Non-FXTAS
groups against CGG repeat size shows that the latter peak
at ∼60 repeats, also showing some overlap with the FXTAS
group.
Relationship of Individual Motor and
Cognitive Impairments to CGG Repeat
Size and FMR1 mRNA Levels
The regression models were applied to the total sample, as
all participants are linked by a common recruitment criterion:
carrier status of the premutation allele. The models were also
applied to the FXTAS group separately, in which participants
are linked by their clinical diagnosis. The results shown in
Figures 1, 2 already suggested that there is a relationship
between clinical manifestations/diagnostic groups and CGG
repeat size within the premutation range on the one hand,
and these manifestations and regional white matter lesions,
on the other. We expanded on these results by assessing
the relationships of all individual wmhs scores, and the
motor and neuropsychological scores included in the study
and listed in Table 1, with genetic predictors: the size of
CGG, and the levels of FMR1 mRNA. The results show
significant associations, in both total and FXTAS samples,
between the combined wmhs (Total-WMH) and infratentorial
wmhs (Infra-DVMH) scores and CGG repeat size; however,
a significant correlation between periventricular wmhs (PV-
WMH) scores and CGG size in the FXTAS sample did
not survive after adjustment of the significance level for
multiple comparisons. The relationship of all three motor
scores with CGG size remained significant after adjustment
for multiple comparisons. In the total sample, amongst the
six cognitive scores, the relationship between CGG repeat
size and Prorated IQ, Similarities and Digit Span remained
significant after adjustment for multiple comparisons, while in
the FXTAS group, the relationship between CGG repeat size and
Prorated IQ, Similarities and SDMT also remained significant
after adjustment. However, after applying a Bonferroni-type of
adjustment, the relationship of CGG repeat size with cognitive
scores was statistically significant only for Similarities, but
remained significant for all motor and wmhs scores (except
PVWMH).
When FMR1 mRNA levels were used as the predictor, highly
significant associations between the level of this transcript and
all wmhs scores were seen in both FXTAS and Total samples,
before and after adjustment for multiple comparisons. However,
a significant association between FMR1 mRNA level and ICARS
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FIGURE 2 | Kernel density distribution for FXTAS and combined Non-FXTAS group, and for OTHERS and Non-affected groups against CGG repeat size.
TABLE 1 | Relationship between each cognitive and motor score with CGG repeat numbers and FMR1 mRNA levels, in the total sample of premutation carriers and in
the FXTAS group.
CGG FMR1 mRNA
Total carriers FXTAS Total carriers FXTAS
N Coef p-Value N Coef p-Value N Coef p-Value N Coef p-Value
MRI scores
Supra-DWMH+ 29 0.02 0.298 16 0.022 0.3715 17 1.969 0.0070∗ 13 2.83 0.0070∗
Infra-DWMH+ 29 0.159 <0.0001∗ 16 0.199 <0.0001∗ 17 2.911 0.0010∗ 13 2.973 <0.0001∗
PV-WMH 29 0.035 0.131 16 0.105 0.0225 17 2.122 0.0001∗ 13 2.466 0.0015∗
Total-WMH 29 0.225 0.0080∗ 16 0.485 0.0002∗ 17 5.778 0.0005∗ 13 7.717 0.0003∗
Motor scores
UPDRS 28 0.123 0.0005∗ 14 0.052 0.1885 15 0.023 0.493 11 0.853 0.281
ICARS 28 0.335 0.0002∗ 14 0.246 0.004∗ 15 1.142 0.381 11 1.947 0.037
Tremor scale 22 0.283 0.0030∗ 10 0.071 0.3395 9 6.54 0.279 7 −1.42 0.472
Cognitive scores
Prorated IQ 30 −0.281 0.028∗ 16 −0.209 0.037 17 0.401 0.4565 13 −1.664 0.3575
Similarities 30 −0.106 0.002∗ 16 −0.08 0.016∗ 17 −0.016 0.492 13 −0.273 0.404
Vocab 26 −0.054 0.025 14 −0.047 0.1145 12 −0.566 0.2015 12 −0.547 0.227
Matrix reasoning 26 −0.06 0.033 14 −0.008 0.4405 14 0.307 0.365 12 0.116 0.4625
Digit span 26 −0.027 0.013∗ 14 0.025 0.3115 13 −0.113 0.4305 12 −0.591 0.2525
SDMT RS 15 −0.434 0.023 8 −0.146 0.014∗ 10 2.17 0.269 8 −1.044 0.4425
p-Values were for one-sided test and ∗< 0.05 after adjustment for multiple comparisons. +Age adjustment applied. Bold figures indicate p-values < 0.05 before
adjustment for multiple comparisons.
score in the FXTAS group did not survive adjustment for multiple
comparisons.
AMPK Activity – A Novel Blood
Biomarker in Relation to Clinical and PM
Status Categories
Because of the highly variable nature of assayed AMPK activity
and the small sample sizes, we combined previously distinguished
categories: OTHERS and Non-affected carriers into the ‘Non-
FXTAS’ group in both descriptive and regression analyses.
The position of each of these two groups relative to normal
controls without any CGG premutation expansion (‘Controls’)
with respect to AMPK activity levels shows a shift of these levels
toward higher values in the Non-FXTAS compared with the
Controls (Figure 3).
The results of statistical comparison between FXTAS, Non-
FXTAS, and Control samples (Table 2) show a highly significant
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FIGURE 3 | Plot of distribution of AMPK activity for FXTAS, Non-FXTAS PM carriers, and Controls without CGG expansions.
TABLE 2 | Descriptive statistics for AMPK activity.
N Mean SD
Control 21 1.07 0.33
FXTAS 14 1.08 0.47
Non-FXTAS 18 1.45 0.48
p-Value = 0.0143 for comparison between the means (ANOVA).
elevation of AMPK activity levels in the Non-FXTAS group
compared with Controls (p = 0.006). In the FXTAS group,
the mean value is considerably lower compared with the Non-
FXTAS group (p = 0.038), and it is not significantly different from
that in the Control sample (p = 0.949). Two-sided test for the
p-values has been considered because a direction of change could
not be anticipated.
Considering the results of these comparisons, it was of
interest to test the assumption that the fall in AMPK activity
levels between Non-FXTAS and FXTAS groups corresponded
to the appearance or increase in severity of tremor/ataxia –
the most typical neurological changes in FXTAS – as measured
by the ICARS scores. The results of regression between these
scores and AMPK activity provided evidence for a highly
significant relationship (coefficient = −1.10, p-value = 0.009),
and the scatterplot shows a continued upward trend in
ICARS scores with a downward trend in AMPK activity
levels, in spite of the extensive variability in the latter values
(Figure 4).
Similar results were obtained for correlation between AMPK
activity levels and the extent of wmhs lesions in the brain:
the relationship between Total WHM and AMPK activity
was significant for the raw values (coefficient = −7.95,
FIGURE 4 | Scatterplot of the log-transformed ICARS scores versus AMPK
activity in the total sample of PM carriers.
p = 0.026), and highly significant for the (square root)
transformed AMPK values (coefficient = −1.68, p = 0.009).
In addition, amongst all five wmhs measures (as in Table 1)
included in the relationship analysis with AMPK activity,
two (Total-WMH and Supra-DWMH) representing the sum
of regional wmhs and supratentorial deep white matter
wmhs, respectively, remained significant after adjustment for
multiple comparisons (coefficients = −7.945 and −3.371,
respectively, with p = 0.026 for both regressions). However,
AMPK activity was not significantly correlated with the two
genetic biomarkers, CGG expansion size and FMR1 mRNA
levels.
Frontiers in Genetics | www.frontiersin.org 7 November 2018 | Volume 9 | Article 531
fgene-09-00531 November 12, 2018 Time: 15:52 # 8
Loesch et al. Neurology and Correlates in Premutation
DISCUSSION
This is the first study to encompass analysis of genetic and cellular
blood biomarkers in relation to each other and to neurological
and cognitive status in an unselected sample of older male
carriers of the FMR1 premutation allele. Although FXTAS is
a major disorder linked to this allele, we draw attention here
to a subgroup of non-FXTAS PM carriers with non-syndromic
features, such as isolated tremor, cognitive decline, fibromyalgia
and mood disorders, in association with non-syndromic or even
occasionally typical wmhs locations. Since the neural pathology in
premutation carriers is linked to a dynamic mutation, implying
continuity of genetic effects, it was of interest to establish the
position of the three clinical groups relative to each other, and
of the pooled non-FXTAS group – comprised of the non-affected
and non-syndromic groups combined – to the FXTAS group in
relation to the distribution of CGG repeat sizes. Our data shows
that while the non-affected carriers were positioned at the lowest
end of the premutation range, including the values bordering
with the gray zone range, the individuals affected with non-
syndromic changes were positioned, with respect to CGG sizes,
between the asymptomatic and FXTAS groups, with the latter
peaking at∼85 CGGs.
This finding is of interest considering the earlier results based
on neuroblastoma-derived human cell cultures, which showed
that a CGG-repeat size threshold of neural toxicity lies between
62 and 95 repeats (Hoem et al., 2011). Moreover, the results
of the same study showed a disparity between FMR1 mRNA
concentration and cell viability at the lower end of the CGG size
distribution in the premutation range of 55–200: the high levels of
apparently ‘toxic’ mRNA below the threshold of the ‘toxic’ CGG
size did not induce cellular toxicity. At the same time, expression
of 95-CGG-repeat mRNA led to reduced cell viability, which
became more pronounced with increasing RNA expression. Our
present data suggesting that the significant relationship between
CGG size and FMR1 mRNA levels might occur exclusively in
the FXTAS group, is in concert with the above findings. While
the Spearman correlation between CGG repeat size and FMR1
mRNA levels (ρ = 0.64) was significant (p = 0.019) in the present
sample of 12 FXTAS patients, with the scatterplot showing a
close linear relationship, it was negligible in a sample of four
non-FXTAS individuals – the result being inconclusive because
of small sample size. However, this clearly indicates the need
to conduct an analysis along the same lines in larger samples,
especially of the non-FXTAS carriers, since the confirmation of
this preliminary observation may contribute to an explanation of
the nature and effects of CGG repeat size in relation to mRNA -
mediated toxicities, including the more recently discovered RAN
translation occurring with FMR1 premutation alleles (Todd et al.,
2013; Boivin et al., 2017). Our new data combined with the
historical findings suggest that concerted action between these
two aspects of genetic pathophysiology characterizing the PM
alleles may be conducive to conversion from the non-affected,
or affected with non-syndromic changes state, to fully-manifest
FXTAS in some carriers, while in some others the non-syndromic
manifestations may represent a different form of PM-associated
condition from FXTAS, not progressing to FXTAS, occupying an
intermediate position between asymptomatic and FXTAS groups
with respect to CGG expansion size, and not displaying the
typical infratentorial wmhs lesion of FXTAS.
Regression analysis revealed relationships of CGG repeat
numbers and FMR1 mRNA levels with the motor and wmhs
measures, and with major cognitive scores. The analysis was
conducted in the FXTAS group, whose subjects have a clinical
diagnosis in common, as well as in the total PM sample,
whose subjects are linked by a common recruitment criterion:
carrier status of the PM allele. The size of the CGG expansion
showed highly significant correlations with all the motor scores,
infratentorial and total wmhs. The relationships with the aspects
of cognitive tests consistent with the established pattern of
cognitive impairments in FXTAS (reviewed by Grigsby et al.,
2014) are less obvious, however, and need to be confirmed in a
larger, independent sample, considering the possibility of type
I errors in the process of FDR control. In an earlier study of
unselected PM carriers (equivalent to our ‘Total carriers’ in
Table 1), Leehey et al. (2008) reported the relationship between
CGG expansion size and a single combined measure using the
three motor scales used in this study. Several other reports were
limited to an association between brain volume loss and CGG
repeat size in a sample of older male PM carriers (Loesch et al.,
2005b) and in a sample of FXTAS males (Cohen et al., 2006; Wang
et al., 2017).
Earlier attempts to relate FMR1 mRNA levels to phenotypic
data in PM carriers have been few, however, and are not readily
comparable to the present study (see Loesch and Hagerman,
2011, for review). This may be because, while there is a close
correspondence in the size of the CGG expansion between blood
and brain cells (Tassone et al., 1999), there are discrepancies
between the levels of mRNA transcript between blood and brain
(Tassone et al., 2004). Nevertheless, our data provide evidence for
the relationships between phenotypic changes and elevated FMR1
mRNA levels in PM carriers. These relationships were strong but
limited to the total and the three regional (Supra-DWMH, Infra-
DWMH, and PV-WMH) wmhs included in this analysis; the only
clinical feature showing significant relationship after adjustment
for multiple comparison was prorated IQ. This result should not
be surprising since white matter lesions (as revealed by MRI)
appear earlier than clinical features. Indeed, subtle changes in the
integrity of white matter (MRI fiber tract changes) may occur
in male carriers without, or prior to, the occurrence of FXTAS
(Battistella et al., 2013; Wang et al., 2013a,b,c).
Notably, our findings that the relationships between both
genetic markers and the clinical/radiological changes were
significant in the Total PM sample, as well as in the FXTAS
group, suggest a progressive effect of increasing FMR1 CGG
expansion size and level of expression of ‘toxic’ mRNA on the
type and severity of neurological manifestations across the whole
spectrum of PM carriers. This effect, may therefore generate mild
and/or atypical manifestations such as encountered in our non-
syndromic (‘OTHERS’) category. Another novel finding from
the present study is that the genotype-phenotype relationships
extend beyond the middle cerebellar peduncles and the adjacent
white matter – the region that has been considered a major
target for FMR1 mRNA toxicity and highly relevant to the
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clinical manifestations of FXTAS (Hagerman and Hagerman,
2013, 2016).
All the above data further illuminates the still unsolved
problem of a diversity of clinical manifestations in PM carriers
ranging from normality to the most severe involvement in the
form of FXTAS, which must clearly depend on the final effect
of interplay, in individual carriers, between cellular stresses
including toxicity of FMR1 mRNA, linked with the chain of
stressful biochemical changes, and cellular stress responses. In
an attempt to make the first step toward understanding this
process, we chose to relate clinical status and the measures of
neurological involvement in PM carriers to the levels of activated
AMPK – a highly sensitive cellular stress response protein
(Hardie et al., 2012). Although these levels were assessed in
cultured lymphoblasts, the only tissue available to us for research
in living subjects, our results provide indirect evidence for this
marker’s relevance to neurological involvement in PM carriers by
showing a significant (inverse) relationship of activated AMPK
levels with the severity of tremor/ataxia (assessed by the ICARS),
and some wmhs measures representing a degree of white matter
pathology, across all three clinical categories of these carriers.
AMPK activity is not the only biochemical change in PM
lymphoblasts that has been found to correlate with the severity
of neurological involvement. We have reported previously that
mitochondrial respiratory function in these cells (rates of basal
and maximal uncoupled O2 consumption, ATP synthesis and
Complex I activity) is positively correlated with wmhs and ICARS
in these carriers (Loesch et al., 2017).
In the present study we observed a significant elevation of
AMPK activity in the non-FXTAS group compared with the levels
in healthy controls and FXTAS patients, as well as, consistent
with this result, negative correlations between the level of this
activity and the ICARS and wmh scores. If these findings are
confirmed in larger samples, they will suggest, in the light of
earlier data (Herrero-Martın et al., 2009; He et al., 2014; Wu et al.,
2014; Distelmaier et al., 2015; Hardie, 2015; Xu et al., 2017) that
AMPK activity in PM carriers may be predominantly protective
against stress-related cellular damage, thereby restraining the
development of mitochondrial dysfunction as seen in FXTAS
(Ross-Inta et al., 2010; Napoli et al., 2011). Notably, AMPK
has been shown to play cytoprotective roles in diverse cell
types, including neuronal cells, cardiomyocytes, fibroblasts, and
epithelial cells. However, only longitudinal studies in larger
samples, considering the three clinical groups as distinguished
in our study, can provide direct evidence that the elevated
AMPK activity in response to cellular stresses in different
individuals is a disease modifier, so that PM individuals with
higher levels of activity are protected, while individuals with
lower levels of activity are more susceptible to the development
of FXTAS. Such future studies would also enable testing of an
alternative hypothesis: that the observed elevation of AMPK
activity in non-FXTAS PM carriers is a predisposing rather
than preventative factor through the pathways leading from
chronic elevation of this enzyme to mitochondrial dysregulation
and neurodegeneration While our preliminary results regarding
AMPK levels and correlations are ambiguous, they may bring us
a step closer to understanding the pathomechanisms of FXTAS
development: rather than implying a lack of meaningful link
between activated AMPK levels and clinical phenotype, the
higher levels of activated AMPK, exclusively in the non-FXTAS
group compared with normal controls (as in Table 2), may be
interpreted as suggestive of its protective role, by preventing
progression of non-FXTAS to FXTAS; whilst the fall of the AMPK
levels from non-FXTAS to FXTAS (as shown by data in Figure 4
and Table 2) may, alternatively, reflect its damaging role by
accelerating neuronal changes toward the FXTAS phenotype.
Apart from small sample sizes, an apparent limitation of this
study is our use of lymphoblasts for functional molecular tests.
However, lymphoblasts have been used successfully to study
the roles of FMR1 mRNA, antisense RNA and FMR1 protein
expression in PM carriers, FXTAS and Fragile-X patients (Ladd
et al., 2007; Hagerman and Hagerman, 2013), and the present
study provides unequivocal evidence for the relationship of
the FMR1 mRNA levels assessed in the lymphoblasts and the
severity of the white matter lesions. Although AMPK activities
have not been studied previously in lymphoblasts from PM
carriers, the relevance of AMPK expression in blood cells
to neurodegenerative diseases as a biomarker and a potential
molecular target in these disorders has recently been reviewed
(Peixoto et al., 2017).
Furthermore, lymphoblasts have been used successfully to
study underlying pathomechanisms in other diseases involving
toxic gain of function RNA or protein aggregates and RAN
translation. Thus, RAN translation producing toxic dipeptide
repeats was measured in lymphoblasts of patients with C9orf72-
associated ALS and frontotemporal dementia (Liu et al., 2014;
Mizielinska and Isaacs, 2014; Niblock et al., 2016).
Most importantly, our own results concerning AMPK have
shown, for the first time, the relevance of this marker in any
human tissue to PM-associated neurological status. However,
we still recommend that this finding should be supported
by studies, in larger samples, using the lymphoblasts, as well
as other tissues available in living humans, or neural cell
tissue in an experimental model. This is especially important
since our results suggest that AMPK may be developed as a
prognostic biomarker/and/or treatment target. Therefore, we
plan to use the AMPK activity test in cultured fibroblasts from
male carriers from different clinical categories and/or at different
stages of the clinical progression. In conclusion, our study has
identified specific links between two major genetic markers
and one cellular stress marker, and the level of neurological
involvement – both clinical and radiological – in an unselected
sample of older male PM carriers. This sample was divided
into three categories depending on the clinical status of the PM
carriers, and we placed particular emphasis on the nature of
this involvement in the non-FXTAS group, and of a transition
from non-affected or non-syndromic status to full-blown FXTAS,
and the underpinning neurodegenerative process. Although the
small sample size did not allow for consideration of this non-
syndromic subgroup separately in some statistical analyses, our
data suggests a link between lower CGG repeat expansion
size within the premutation range and the occurrence of non-
syndromic neurological changes. Further investigation based on
a longitudinal study of larger cohorts will be necessary to establish
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what proportion of these subjects represents preclinical stages
of FXTAS, and what proportion remains in the non-syndromic
clinical category.
Questions about the mechanism by which AMPK is
dramatically elevated in the non-FXTAS carriers compared with
healthy controls and normalizes in the fully syndromic FXTAS
group should be explored in larger samples, including all three
clinical groups, as distinguished here, in a longitudinal study. If
the role of AMPK is confirmed and the mechanism is determined,
this will open a new avenue of research into the dynamics of the
effects of PM alleles on cellular functions and pathology, as well
as providing a new biomarker of clinical status, and a potential
disease-modifying/preventative target.
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